Corrigendum: Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority phase III trail

Q1 Medicine
{"title":"Corrigendum: Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority phase III trail","authors":"","doi":"10.1002/cdt3.93","DOIUrl":null,"url":null,"abstract":"<p>In the article titled, “Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail” published in pages 59-70, issue 1, vol. 8 of Chronic Diseases and Translational Medicine,<span><sup>1</sup></span> the information of trial registration at the end of Abstract is missing. The registration information should be: This study has been registered on www.chinadrugtrials.org.cn, registered number CTR20130080.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"10 1","pages":"81"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.93","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Diseases and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cdt3.93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In the article titled, “Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail” published in pages 59-70, issue 1, vol. 8 of Chronic Diseases and Translational Medicine,1 the information of trial registration at the end of Abstract is missing. The registration information should be: This study has been registered on www.chinadrugtrials.org.cn, registered number CTR20130080.

更正:治疗中国慢性肾衰竭血液透析患者贫血的达贝特α注射液与环氧乙烷α注射液:随机、开放标签、平行分组、非劣效性III期试验
慢性病与转化医学》1 第 8 卷第 1 期第 59-70 页刊登了题为 "达贝泊汀α注射液与环氧乙烷α注射液治疗中国慢性肾衰竭血液透析患者贫血的比较:慢性病与转化医学》(Chronic Diseases and Translational Medicine)1 第 8 卷第 1 期第 59-70 页发表的文章《达贝泊肽α注射液与环氧乙烷α注射液治疗中国慢性肾衰血液透析患者贫血:随机、开放标签、平行组、非劣效 III 期试验》(A randomized, open-label, parallel-group, non-inferiority Phase III trail)中,摘要末尾缺少试验注册信息。注册信息应为本研究已在 www.chinadrugtrials.org.cn 上注册,注册号为 CTR20130080。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
195
审稿时长
35 weeks
期刊介绍: This journal aims to promote progress from basic research to clinical practice and to provide a forum for communication among basic, translational, and clinical research practitioners and physicians from all relevant disciplines. Chronic diseases such as cardiovascular diseases, cancer, diabetes, stroke, chronic respiratory diseases (such as asthma and COPD), chronic kidney diseases, and related translational research. Topics of interest for Chronic Diseases and Translational Medicine include Research and commentary on models of chronic diseases with significant implications for disease diagnosis and treatment Investigative studies of human biology with an emphasis on disease Perspectives and reviews on research topics that discuss the implications of findings from the viewpoints of basic science and clinical practic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信